JESUS MIGUEL
UNDA URZAIZ
Investigador/a en el periodo 2002-2023
Hospital Miguel Servet
Zaragoza, EspañaPublicaciones en colaboración con investigadoras/es de Hospital Miguel Servet (9)
2023
-
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer
Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126
-
Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply
Actas Urologicas Espanolas
-
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
European urology oncology, Vol. 6, Núm. 1, pp. 58-66
2017
-
Consenso sobre el manejo del cáncer de próstata resistente a la castración avanzado en España
Archivos Espanoles de Urologia, Vol. 70, Núm. 9, pp. 777-791
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2011
2009
-
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203
2008
-
Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
European Urology, Vol. 53, Núm. 5, pp. 992-1002